BGF MDI 320/28.8/9.6 μg

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Asthma

Phase 3

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

CompletedNCT04609878

AstraZenecaAsthma

Start: 2020-12-15End: 2025-03-21Updated: 2026-06-30

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

CompletedNCT04609904

AstraZenecaAsthma

Start: 2021-03-01End: 2025-03-20Updated: 2026-07-02

Related Papers

Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS

International Journal of COPD2024-12-012 citations